SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

30 يناير 2025 07:00:50 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

13 يناير 2025 06:30:33 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

03 يناير 2025 06:30:46 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

26 نوفمبر 2024 07:00:26 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

12 نوفمبر 2024 09:25:59 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

12 نوفمبر 2024 06:30:21 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

11 نوفمبر 2024 07:00:56 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

11 نوفمبر 2024 06:30:11 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

07 نوفمبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

05 نوفمبر 2024 07:00:32 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

22 أكتوبر 2024 07:00:14 بحسب Nasdaq GlobeNewswire

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

28 أغسطس 2024 06:30:35 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

07 أغسطس 2024 06:30:35 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

29 يوليو 2024 06:30:11 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

23 يوليو 2024 07:00:02 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

01 يوليو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

05 يونيو 2024 07:00:52 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 مايو 2024 17:13:28 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

08 مايو 2024 07:00:27 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

02 مايو 2024 06:30:00 بحسب Nasdaq GlobeNewswire